Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

LESSONS LEARNED. A phase I study of the pan‐class I phosphoinositide 3‐kinase inhibitor pilaralisib (in capsule formulation) in advanced solid tumors established the maximum tolerated dose as 600 mg once daily. The current study investigated pilaralisib in tablet formulation. Pilaralisib tablets wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelman, Gerald, Rodon, Jordi, Lager, Joanne, Castell, Christelle, Jiang, Jason, Van Allen, Eliezer M., Wagle, Nikhil, Lindeman, Neal I., Sholl, Lynette M., Shapiro, Geoffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896717/
https://www.ncbi.nlm.nih.gov/pubmed/29593099
http://dx.doi.org/10.1634/theoncologist.2017-0691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896717/
https://www.ncbi.nlm.nih.gov/pubmed/29593099
http://dx.doi.org/10.1634/theoncologist.2017-0691

Ejemplares similares